- Relay Therapeutics (RLAY) is a clinical-stage precision medicines company focused on targeted oncology, with a $4.4 billion market cap.
- RLAY has surged 486% over the past year.
- Shares are trading near a new 3-year high.
- Technical momentum is strong, but fundamentals show that revenue is expected to decrease by more than 30% this year.